Viking says oral VK2735 cuts weight up to 12.2% in Phase 2 trial

Viking Therapeutics

Viking Therapeutics

VKTX

0.00
  • Viking Therapeutics presented additional Phase 2 data at European Congress on Obesity 2026 from VENTURE-Oral Dosing trial of oral VK2735, an obesity drug candidate designed for once-daily use.
  • Trial showed progressive, dose-related weight loss over 13 weeks, with results indicating continued improvement through study end rather than leveling off.
  • Safety profile was broadly consistent with incretin-based obesity therapies, with most side effects reported as manageable and occurring early in treatment.
  • Data are being used to shape oral Phase 3 registration studies, which Viking expects to start later in 2026, alongside ongoing Phase 3 testing of injectable VK2735.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605120705PR_NEWS_USPR_____LA57098) on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.